Agios Pharmaceuticals, Inc.
0HB0.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.9B
Close$
Share Statistics
| Market cap | $1.90 Billion |
|---|---|
| Enterprise Value | $1.83 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.12 |
| Beta | 0.54 |
| Outstanding Shares | 59,488,871 |
Return
| Return on Equity | -40.09% |
|---|---|
| Return on Assets | -37.11% |
| Return on Invested Capital | -44.21% |
Valuation & Multiples
| P/E Ratio | -4.54 |
|---|---|
| PEG | 44.92 |
| Price to Sales | 30.26 |
| Price to Book Ratio | 1.78 |
| Enterprise Value to Revenue | 18.62 |
| Enterprise Value to EBIT | -3.99 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-1.65
Average shareholder expectationRevenue Estimate
$26.40 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.22
Average shareholder expectationRevenue Estimate
$53.40 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Agios Pharmaceuticals Inc
536 employees
CEO: Jacqualyn Fouse Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...